Horizon Therapeutics (NASDAQ:HZNP) had its price objective hoisted by JMP Securities to in a research report released on Tuesday, The Fly reports. JMP Securities currently has an outperform rating on the biopharmaceutical company’s stock.
Several other research firms also recently commented on HZNP. Stifel Nicolaus raised their price objective on shares of Horizon Therapeutics from $35.00 to $40.00 and gave the stock a buy rating in a report on Monday, December 16th. Piper Jaffray Companies reiterated a buy rating and issued a $49.00 price objective (up from $36.00) on shares of Horizon Therapeutics in a research note on Tuesday, December 24th. Morgan Stanley boosted their target price on shares of Horizon Therapeutics from $32.00 to $38.00 and gave the company an overweight rating in a report on Monday, December 16th. Jefferies Financial Group increased their target price on Horizon Therapeutics from $35.00 to $40.00 and gave the stock a buy rating in a research report on Monday, December 16th. Finally, Cantor Fitzgerald raised their price target on Horizon Therapeutics from $32.00 to $36.00 and gave the stock an overweight rating in a report on Friday, November 8th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $37.14.
NASDAQ HZNP traded up $0.18 during trading hours on Tuesday, reaching $38.47. 330,372 shares of the company were exchanged, compared to its average volume of 1,724,118. Horizon Therapeutics has a 1 year low of $20.05 and a 1 year high of $38.78. The business’s 50 day simple moving average is $34.97 and its 200-day simple moving average is $28.98. The company has a quick ratio of 2.23, a current ratio of 2.33 and a debt-to-equity ratio of 0.87. The stock has a market capitalization of $7.17 billion, a P/E ratio of 21.02, a P/E/G ratio of 1.62 and a beta of 0.89.
In other news, EVP Brian K. Beeler sold 12,475 shares of Horizon Therapeutics stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $30.02, for a total value of $374,499.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jeff Kent sold 3,545 shares of Horizon Therapeutics stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $36.50, for a total value of $129,392.50. Following the completion of the transaction, the insider now owns 121,988 shares of the company’s stock, valued at $4,452,562. The disclosure for this sale can be found here. Over the last quarter, insiders sold 126,888 shares of company stock valued at $4,413,598. 4.10% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in HZNP. IFP Advisors Inc grew its position in shares of Horizon Therapeutics by 163.0% in the fourth quarter. IFP Advisors Inc now owns 1,086 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 673 shares in the last quarter. Quadrant Capital Group LLC purchased a new position in Horizon Therapeutics during the third quarter worth about $66,000. Tower Research Capital LLC TRC grew its position in Horizon Therapeutics by 384.1% during the second quarter. Tower Research Capital LLC TRC now owns 3,389 shares of the biopharmaceutical company’s stock worth $82,000 after buying an additional 2,689 shares in the last quarter. Bank of Montreal Can grew its position in Horizon Therapeutics by 45.7% during the second quarter. Bank of Montreal Can now owns 3,831 shares of the biopharmaceutical company’s stock worth $92,000 after buying an additional 1,201 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in Horizon Therapeutics during the second quarter worth about $125,000. Institutional investors own 88.24% of the company’s stock.
Horizon Therapeutics Company Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
See Also: Roth IRA
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.